USP22 and breast carcinoma: Indeed, comparison analysis by western blotting and flow cytometry of integrin family members between WT and USP22-null breast cancer cells detected a dramatic reduction in integrin b1 expression by USP22 inhibition in both mouse 4T1 and patient-derived L2G+ TN1 cells (Fig. 2B–D).